NEWS & EVENTS 
SPECIALTY CARE
Diabetes medication prescribers can now reference an updated 2024 Dosing Guide for Incretin Mimetics and SGLT2 Inhibitors.
Completely revamped, this updated dosing guide now includes dual GLP-1 RA/GIP, enhanced renal dosing, and all FDA indications. Replace the original 2022 document with this important update.
Initially launched in 2022, the Incretin Mimetics and SGLT2 Inhibitor Dosing Guide was one of the first MCT2D point-of-care tools. It provides easy-to-reference comparison tables for the two classes of diabetes medications, detailing medication dosing amount; frequency, titration, escalation; and renal adjustments. Here's what some of our members had to say about this tool:
I liked how it was easy to read and follow the chart to which conversion for my patient I would be doing. The medications are so hard to find that when they were using different medications either due to insurance coverage or lack of meds I could keep them on a comparable dose.
Another member shared:
The charts for the dosing and indications for each medication was very helpful in choosing which one for my patient. Which SGLT 2 were approved for heart failure, CKD with albuminuria, and ASCVD. The GLP1 dosing chart helpful for titration and dosing with CKD.
Subscribe to the MCT2D Newsletter
Once per month we deliver news, updates, events, and more directly to you!
ccteam@mct2d.org
Support for The Michigan Collaborative for Type 2 Diabetes (MCT2D) is provided by Blue Cross Blue Shield of Michigan as part of the BCBSM Value Partnerships program.
Although Blue Cross Blue Shield of Michigan and MCT2D work collaboratively, the opinions, beliefs and viewpoints expressed by the author do not necessarily reflect the opinions, beliefs and viewpoints of BCBSM or any of its employees.